# Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-2026-rbc-capital-markets-global-healthcare-conf-303e3f76
Ticker: WVE
Company: Wave Life Sciences
Source: Wave Life Sciences
Published: 2026-05-13 20:05 EST
## Summary

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the...

## Article Body
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City on Wednesday, May 20, 2026 at 8:00 a.m. ET.

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events . A replay of this presentation will be archived and available on the site for a limited time following the event.

About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn .

Contact: Kate Rausch VP, Corporate Affairs and Investor Relations +1 617-949-4827

Investors: James Salierno Director, Investor Relations +1 617-949-4043 InvestorRelations@wavelifesci.com

Media : Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 MediaRelations@wavelifesci.com
## Recent Company News
- 2026-07-23 12:30 EST — [Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026](https://biopharmsignal.com/news/WVE/wave-life-sciences-second-quarter-2026-financial-results-scheduled-for-july-30-2-a9974bb9) — Source: Wave Life Sciences
- 2026-07-07 20:15 EST — [Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026--d94f52e6) — Source: Wave Life Sciences
- 2026-06-24 12:30 EST — [Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-initiation-of-phase-2a-portion-of-inlight-trial-of--2b38bb83) — Source: Wave Life Sciences
- 2026-06-01 12:30 EST — [Wave Life Sciences to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-c00fcf01) — Source: Wave Life Sciences
- 2026-05-18 20:30 EST — [Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-positive-update-on-restoraation-2-trial-wve-006-gal-3518234b) — Source: Wave Life Sciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)